Cancer Patients With Clonal Hematopoiesis Die From Primary Malignancy or Comorbidities Despite Higher Rates of Transformation to Myeloid Neoplasms

Authors

Kelly S Chien
Faustine Ong
Kunhwa Kim
Ziyi Li
Rashmi Kanagal-Shamanna
Courtney D DiNardo
Koichi Takahashi
Guillermo Montalban-Bravo
Danielle Hammond
Koji Sasaki
Sherry A Pierce
Hagop M Kantarjian
Guillermo Garcia-Manero

Publication Date

3-1-2024

Journal

Cancer Medicine

Abstract

BACKGROUND: The occurrence of somatic mutations in patients with no evidence of hematological disorders is called clonal hematopoiesis (CH). CH, whose subtypes include CH of indeterminate potential and clonal cytopenia of undetermined significance, has been associated with both hematologic cancers and systemic comorbidities. However, CH's effect on patients, especially those with concomitant malignancies, is not fully understood.

METHODS: We performed a retrospective evaluation of all patients with CH at a tertiary cancer center. Patient characteristics, mutational data, and outcomes were collected and analyzed.

RESULTS: Of 78 individuals included, 59 (76%) had a history of cancer and 60 (77%) had moderate to severe comorbidity burdens. DNMT3A, TET2, TP53, and ASXL1 were the most common mutations. For the entire cohort, the 2-year overall survival rate was 79% (95% CI: 70, 90), while the median survival was not reached. Of 20 observed deaths, most were related to primary malignancies (n = 7, 35%), comorbidities (n = 4, 20%), or myeloid neoplasms (n = 4, 20%). Twelve patients (15%) experienced transformation to a myeloid neoplasm. According to the clonal hematopoiesis risk score, the 3-year transformation rate was 0% in low-risk, 15% in intermediate-risk (p = 0.098), and 28% in high-risk (p = 0.05) patients. By multivariate analysis, transformation was associated with variant allele frequency ≥0.2 and hemoglobin/dL.

CONCLUSIONS: In a population including mostly cancer patients, CH was associated with comorbidities and myeloid transformation in patients with higher mutational burdens and anemia. Nevertheless, such patients were less likely to die of their myeloid neoplasm than of primary malignancy or comorbidities.

Keywords

Humans, Clonal Hematopoiesis, Retrospective Studies, Hematopoiesis, Neoplasms, Myeloproliferative Disorders, Comorbidity

Comments

Associated Data

PMID: 38497538